Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma

PURPOSE: Gemcitabine plus cisplatin is active in malignant mesothelioma (MM), although single-arm phase II trials have reported variable outcomes. Vascular endothelial growth factor (VEGF) inhibitors have activity against MM in preclinical models. We added the anti-VEGF antibody bevacizumab to gemci...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Kindler, Hedy L., Karrison, Theodore G., Gandara, David R., Lu, Charles, Krug, Lee M., Stevenson, James P., Jänne, Pasi A., Quinn, David I., Koczywas, Marianna N., Brahmer, Julie R., Albain, Kathy S., Taber, David A., Armato, Samuel G., Vogelzang, Nicholas J., Chen, Helen X., Stadler, Walter M., Vokes, Everett E.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2012
Konular:
Original Reports
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3397785/
https://ncbi.nlm.nih.gov/pubmed/22665541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.41.5869
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller